There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Genmab (GMAB – Research Report), BioMarin Pharmaceutical (BMRN – Research Report) and Greenwich LifeSciences (GLSI – Research Report) with bullish sentiments.
Genmab (GMAB)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab, with a price target of $50.00. The company’s shares closed last Friday at $28.71, close to its 52-week low of $26.32.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Genmab has an analyst consensus of Hold, with a price target consensus of $40.40, which is a 42.0% upside from current levels. In a report issued on February 15, BTIG also maintained a Buy rating on the stock with a $46.00 price target.
See the top stocks recommended by analysts >>
BioMarin Pharmaceutical (BMRN)
In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $111.00. The company’s shares closed last Friday at $88.77.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $107.45 average price target.
Greenwich LifeSciences (GLSI)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Greenwich LifeSciences today and set a price target of $36.00. The company’s shares closed last Friday at $11.24.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Greenwich LifeSciences has an analyst consensus of Moderate Buy, with a price target consensus of $36.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMAB:
- Transactions in connection with share buy-back program
- Notice to Convene the Annual General Meeting of Genmab A/S
- Genmab Files Annual Report with the U.S. Securities and Exchange Commission
- Genmab Announces Initiation of Share Buy-Back Program
- Genmab initiating share buy-back program for up to 190,000 shares
